Chart suggests earlier signs of recovery, page-15

They got FDA approval less than 2 years ago. Saying they have set the company back 2 years and not met any targets is a bit of a stretch. Some milestones have not been met and the old ‘imminent’ sale was frustrating however they have in turn revised their strategy and I envisage they are clearly focused on meeting their 2020 goal cash flow wise while hitting targets and communicating more clearly to the market. Sometimes patience is a virtue. If the changes you suggest were to occur and the company was set back 6-12 months well kiss your cash flow positive by 2020 goodbye and say hello to a cap raise. I have asked myself why the non-exec resigned and there are many reasons, you obviously take a certain view while myself for one does not, each to their own.